About 11,100 results

ALLMedicine™ Alzheimer Disease Center

Research & Reviews  4,004 results

Cerebral Small Vessel Disease in Sporadic and Familial Alzheimer Disease.
The American Journal of Pathology; Kalaria RN, Sepulveda-Falla D

Aug 1st, 2021 - Alzheimer's disease is the most common cause of dementia. Biological definitions of AD are limited to the cerebral burden of amyloid β plaques, neurofibrillary pathology and neurodegeneration. However, current evidence suggests various features of...

Astrocytic IL-3 could help microglia protect against Alzheimer disease.
https://doi.org/10.1038/s41582-021-00546-0 10.1038/s41586-021-03734-6 10.1038/d41586-021-01870-7
Nature Reviews. Neurology; Wood H

Jul 30th, 2021 - Astrocytic IL-3 could help microglia protect against Alzheimer disease.|2021|Wood H,|

Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and lat...
https://doi.org/10.1007/s00401-021-02342-y 10.1073/pnas.1317918110 10.2967/jnumed.112.113654 10.1007/BF00308809 10.1021/ja991233x 10.18637/jss.v045.i03 10.1111/neup.12205 10.1016/S0091-679X(08)62098-1 10.1212/WNL.0000000000004539 10.1002/acn3.51237 10.1016/S1474-4422(12)70142-4 10.1016/j.jalz.2016.04.006 10.1001/jamaneurol.2014.4144 10.1016/S0306-4522(01)00169-5 10.1364/optica.388157 10.1007/s00401-012-1025-1 10.1214/009053606000001460 10.1038/s41598-018-21641-1 10.1016/S0896-6273(02)00569-X 10.1097/00005072-199311000-00011 10.1016/S1474-4422(18)30028-0 10.1074/jbc.270.13.7013 10.1212/WNL.0000000000004643 10.1016/j.jalz.2018.04.011 10.1016/j.jalz.2011.10.007 10.1186/s40478-016-0399-z 10.1093/brain/awn016 10.1016/S1474-4422(12)70291-0 10.1016/S1474-4422(09)70299-6 10.1002/ana.21164 10.1016/j.jalz.2018.09.001 10.1016/0304-3940(95)11678-P 10.1002/ana.20009 10.1016/j.jalz.2014.07.003 10.1523/JNEUROSCI.2990-05.2005 10.1523/JNEUROSCI.0730-07.2007 10.1073/pnas.96.9.5274 10.1093/brain/awn107 10.1074/jbc.271.52.33623 10.1007/s00415-005-0019-5 10.1006/nbdi.1996.0003 10.1093/brain/awm191 10.2967/jnumed.117.204271 10.1212/WNL.0b013e3181cef7e3 10.1186/1750-1326-3-20 10.1212/wnl.41.4.479 10.1007/s00401-011-0910-3 10.4155/cli.12.93 10.1093/brain/awv050 10.1097/NEN.0b013e31825018f7 10.1093/brain/awz099 10.1001/archneur.57.6.869 10.1186/1750-1326-5-2 10.1016/j.neurobiolaging.2009.04.002 10.1001/archneur.65.4.540 10.1093/JNEN/NLV028 10.1093/brain/awx057 10.1212/WNL.0000000000000596 10.1016/j.jalz.2015.02.004 10.1212/WNL.0b013e31825fdf18 10.1007/s00401-020-02249-0 10.1016/j.neuroimage.2014.11.058 10.1371/journal.pone.0073377 10.1016/j.nicl.2018.04.022 10.1016/S1474-4422(16)30229-0 10.1007/s00401-018-1897-9 10.1186/s40478-019-0837-9 10.1212/WNL.58.12.1791 10.1097/00005072-199902000-00010 10.1002/humu.20402 10.1002/ana.21321 10.3109/13506129.2013.797389 10.1016/S1474-4422(13)70044-9 10.1002/ana.410300503 10.2967/jnumed.109.069088
Acta Neuropathologica; Chen CD, Joseph-Mathurin N et. al.

Jul 29th, 2021 - Pittsburgh compound B (PiB) radiotracer for positron emission tomography (PET) imaging can bind to different types of amyloid-β plaques and blood vessels (cerebral amyloid angiopathy). However, the relative contributions of different plaque subtyp...

Lysosomal TPCN (two pore segment channel) inhibition ameliorates beta-amyloid pathology...
Autophagy Tong BC, Wu AJ et. al.

Jul 28th, 2021 - Aβ: β-amyloid; AD: Alzheimer disease; AIF1/IBA1: allograft inflammatory factor 1; ALP: autophagy-lysosomal pathway; APP: amyloid beta precursor protein; ATP6V1B1/V-ATPase V1b1: ATPase H+ transporting V1 subunit B1; AVs: autophagy vacuoles; BAF: ba...

A network pharmacology approach to uncover the key ingredients in Ginkgo Folium and the...
Aging Zeng P, Fang M et. al.

Jul 28th, 2021 - This study aimed to identify potential anti-Alzheimer's disease (AD) targets and action mechanisms of Ginkgo Folium (GF) through a network pharmacology approach. Eighty-four potential targets of 10 active anti-AD ingredients of GF were identified,...

see more →

Guidelines  6 results

ACR Appropriateness Criteria® Dementia.
Journal of the American College of Radiology : JACR; , Moonis G et. al.

May 7th, 2020 - Degenerative disease of the central nervous system is a growing public health concern. The primary role of neuroimaging in the workup of patients with probable or possible Alzheimer disease has typically been to exclude other significant intracran...

Falls Risk and Alzheimer Disease: A Patient Guide.
Archives of Physical Medicine and Rehabilitation; Kahya M, Sood P et. al.

Mar 3rd, 2020 - Falls Risk and Alzheimer Disease: A Patient Guide.|2020|Kahya M,Sood P,Devos H,Krishnan S,Hirsch MA,|

Diagnostic criteria for vascular cognitive disorders: a VASCOG statement.
Alzheimer Disease and Associated Disorders; Sachdev P, Kalaria R et. al.

Mar 19th, 2014 - Several sets of diagnostic criteria have been published for vascular dementia since the 1960s. The continuing ambiguity in vascular dementia definition warrants a critical reexamination. Participants at a special symposium of the International Soc...

Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cogn...
Alzheimer's & Dementia : the Journal of the Alzheimer's A... Johnson KA, Minoshima S et. al.

Jul 3rd, 2013 - Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. The Amyloid Imaging Task Force of the Alzheimer's Association and S...

Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the ...
Genetics in Medicine : Official Journal of the American C... Goldman JS, Hahn SE et. al.

May 18th, 2011 - Alzheimer disease is the most common cause of dementia. It occurs worldwide and affects all ethnic groups. The incidence of Alzheimer disease is increasing due, in part, to increased life expectancy and the aging baby boomer generation. The averag...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  81 results

Deep Brain Stimulation With LIFUP for Mild Cognitive Impairment and Mild Alzheimer's Disease

Mar 23rd, 2020 - Alzheimer disease (AD) is a neurodegenerative condition and the most common cause of dementia or a functional impairment in memory and other cognitive abilities. Prior to developing the functional impairment of dementia, patients develop mild cogn...

18-Month Study of Memory Effects of Curcumin

Mar 3rd, 2020 - Several lines of evidence suggest that the neuropathological and clinical decline leading to Alzheimer disease (AD) begins years before patients develop the full AD clinical syndrome (NINCDS-ADRDA diagnostic criteria; McKhann et al, 1984). Mild me...

Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs

Mar 2nd, 2020 - AD is one of the most common mental disorders of late life. Preliminary studies indicate that anti-inflammatory drugs may attenuate or prevent AD symptoms, but efficacy trials are needed. Participants in this study will be randomly assigned to rec...

Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans

Feb 18th, 2020 - The purpose of this research study is to evaluate a new radioactive compound used in positron emission tomography (PET) scans in identifying tau tangles (a certain protein that might be associated with Alzheimer's disease) in the brain, and if the...

Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.

Aug 21st, 2019 - Hypothesis had been performed that PET with 18F-Flutemetamol (Vizamyl®) could lead an early diagnostic. Indeed, this tracer had been recently used to highlight inter-cerebral beta-amyloid plaques on patients with Alzheimer Disease. Because this la...

see more →

News  344 results

Mild Cognitive Impairment with Lewy Bodies or Alzheimer’s Disease and Risk of Progression to Dementia

Apr 26th, 2021 - Takeaway Patients with mild cognitive impairment (MCI) and clinical characteristics of dementia with Lewy bodies (DLB) had a worse prognosis than MCI-Alzheimer’s disease (MCI-AD), with an increased annual risk of transition from MCI to dementia. M...

TDP-43 Protein Declines Years Before Death in Alzheimer's

Nov 9th, 2020 - Brain levels of TAR DNA binding protein 43 (TDP-43), a key factor in the neurodegeneration that occurs with Alzheimer's disease, begin declining nearly two decades prior to the end of life and show an independent effect on the rate of hippocampal ...

Fast Five Quiz: Alzheimer Disease Management

Aug 19th, 2020 - Alzheimer disease is a chronic, neurodegenerative disorder of the aging population that results in progressive cognitive and behavioral dysfunction. Afflicting more than 6 million Americans and more than 8 million Europeans, Alzheimer disease is t...

Fast Five Quiz: Alzheimer Disease Management

Aug 19th, 2020 - Answer 1/5 Which of the following is the current standard pharmacologic treatment for Alzheimer disease in the United States and Europe? Your peers chose: Carbidopa/levodopa/entacapone 0% Cholinesterase inhibitors (ChEIs) and partial N-methyl-D-as...

Fast Five Quiz: Alzheimer Disease Management

Aug 19th, 2020 - In addition to the medications approved for Alzheimer disease, regular physical and cognitive exercise routines are strategies to prevent and slow disease progression. Increased cardiorespiratory fitness levels are associated with higher hippocamp...

see more →